Aviv Scientific Raises $40 Million In Series B Funding To Create The World’S First High Dimensional Omics Database Of The Aging Process

Today world leader in research and clinical treatment of age-related cognitive and functional decline to maximize human performance, Aviv Scientific, announces the closing of $40 million in a oversubscribed Series B funding round. Led by Israel’s largest public medical services conglomerate, Danel LTD; Jeff Horing’s Deep Insight Fund; the country’s most successful high-tech angels and entrepreneurs; international longevity and healthspan optimization focused investors; the Series B fundraise will accelerate the global rollout of its network of medical clinics and the development of the Aviv Aging Database. For the first time, in depth comprehensive OMICS data detailing the aging process in healthy adults will be captured, expediting the development of therapeutics and approaches to notably extend healthspan, and ultimately lifespan, in humans.